Photo from Umang Swami/X
Aug 5, 2024, 02:38
Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer
Umang Swami, Oncologist at Huntsman Cancer Institute, University of Utah, shared a post on X about a recent paper titled “Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States” published in Future Oncology.
Authors: Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar and Sumati Gupta.
“Just in Future Oncology. One of the largest real world studies evaluating TRT trends in nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common TRT.”
Source: Umang Swami/X
ADT
ADT+NSAA
Agnes Hong
Benjamin Chastek
Bin Xie
Brandon Diessner
cancer
Christopher Young
Future Oncology
Huntsman Cancer Institute
Krishnan Ramaswamy
Nader El Chaar
NHT
nmCRPC
nonmetastatic castration-resistant prostate cancer
OncoDaily
Oncology
Scott H Bunner
Sumati Gupta
TRT
Umang Swami
University of Utah
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28
Nov 13, 2024, 23:26
Nov 13, 2024, 23:22
Nov 13, 2024, 23:18
Nov 13, 2024, 19:25